Literature DB >> 22760966

Proteomics, genomics, and molecular biology in the personalized treatment of colorectal cancer.

John M Carethers1.   

Abstract

Colorectal cancer develops and progresses from genetic and genomic changes that occur within and transforms the growth behavior of a normal colonic cell. Molecular tools have advanced enough to allow the scientific community to probe deeper into risk alleles within a population as well as into individual patient genetic data that can ascribe such a risk. Detected genetic and genomic changes from colorectal cancer can help determine a patient's prognosis, predict response to chemotherapy, and determine the approach to care with biological therapies. Utilizing stool, blood/plasma, and tumor tissue to obtain genetic, genomic, and pharmacokinetic information contribute to a person's profile to direct specific cancer care.

Entities:  

Mesh：

Year:  2012        PMID： 22760966      PMCID： PMC3424282          DOI： 10.1007/s11605-012-1942-2

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN： 1091-255X            Impact factor:   3.452


  25 in total

Review 1.  Colorectal cancer molecular biology moves into clinical practice.

Authors:  Colin C Pritchard; William M Grady
Journal:  Gut       Date:  2010-10-04       Impact factor: 23.059

2.  Systemic treatment of advanced colorectal cancer: tailoring therapy to the tumor.

Authors:  John M Carethers
Journal:  Therap Adv Gastroenterol       Date:  2008-07       Impact factor: 4.409

3.  Should African Americans be screened for colorectal cancer at an earlier age?

Authors:  John M Carethers
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2005-08

4.  Predicting cancer drug response by proteomic profiling.

Authors:  Yan Ma; Zhenyu Ding; Yong Qian; Xianglin Shi; Vince Castranova; E James Harner; Lan Guo
Journal:  Clin Cancer Res       Date:  2006-08-01       Impact factor: 12.531

5.  Mismatch repair proficiency and in vitro response to 5-fluorouracil.

Authors:  J M Carethers; D P Chauhan; D Fink; S Nebel; R S Bresalier; S B Howell; C R Boland
Journal:  Gastroenterology       Date:  1999-07       Impact factor: 22.682

6.  Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland.

Authors:  P Lichtenstein; N V Holm; P K Verkasalo; A Iliadou; J Kaprio; M Koskenvuo; E Pukkala; A Skytthe; K Hemminki
Journal:  N Engl J Med       Date:  2000-07-13       Impact factor: 91.245

7.  Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.

Authors:  Christine M Ribic; Daniel J Sargent; Malcolm J Moore; Stephen N Thibodeau; Amy J French; Richard M Goldberg; Stanley R Hamilton; Pierre Laurent-Puig; Robert Gryfe; Lois E Shepherd; Dongsheng Tu; Mark Redston; Steven Gallinger
Journal:  N Engl J Med       Date:  2003-07-17       Impact factor: 91.245

Review 8.  The human gut microbiome: implications for future health care.

Authors:  James M Kinross; Alexander C von Roon; Elaine Holmes; Ara Darzi; Jeremy K Nicholson
Journal:  Curr Gastroenterol Rep       Date:  2008-08

Review 9.  Genomic and epigenetic instability in colorectal cancer pathogenesis.

Authors:  William M Grady; John M Carethers
Journal:  Gastroenterology       Date:  2008-09-04       Impact factor: 22.682

10.  Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines.

Authors:  Christian N Arnold; Ajay Goel; C Richard Boland
Journal:  Int J Cancer       Date:  2003-08-10       Impact factor: 7.396
View more
  10 in total

1.  Up-regulation of neutrophil gelatinase-associated lipocalin in colorectal cancer predicts poor patient survival.

Authors:  Herbert Thomas Maier; Felix Aigner; Birgit Trenkwalder; Matthias Zitt; Natalie Vallant; Alexander Perathoner; Christian Margreiter; Patrizia Moser; Johann Pratschke; Albert Amberger
Journal:  World J Surg       Date:  2014-08       Impact factor: 3.352

2.  HEREDITARY, SPORADIC AND METASTATIC COLORECTAL CANCER ARE COMMONLY DRIVEN BY SPECIFIC SPECTRUMS OF DEFECTIVE DNA MISMATCH REPAIR COMPONENTS.

Authors:  John M Carethers
Journal:  Trans Am Clin Climatol Assoc       Date:  2016

Review 3.  DNA testing and molecular screening for colon cancer.

Authors:  John M Carethers
Journal:  Clin Gastroenterol Hepatol       Date:  2013-12-17       Impact factor: 11.382

Review 4.  Screening for colorectal cancer in African Americans: determinants and rationale for an earlier age to commence screening.

Authors:  John M Carethers
Journal:  Dig Dis Sci       Date:  2014-12-25       Impact factor: 3.199

5.  Current and Future Role of the Gastroenterologist in GI Cancer Management.

Authors:  John M Carethers
Journal:  J Dig Cancer Rep       Date:  2013-11

Review 6.  Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer.

Authors:  John M Carethers; Barbara H Jung
Journal:  Gastroenterology       Date:  2015-07-26       Impact factor: 22.682

7.  Biomarker-directed Targeted Therapy in Colorectal Cancer.

Authors:  John M Carethers
Journal:  J Dig Cancer Rep       Date:  2015-06

8.  Molecular characterization of colorectal cancer patients and concomitant patient-derived tumor cell establishment.

Authors:  Haa-Na Song; Chung Lee; Seung Tae Kim; Sun Young Kim; Nayoung K D Kim; Jiryeon Jang; Mihyun Kang; Hyojin Jang; Soomin Ahn; Seok Hyeong Kim; Yoona Park; Yong Beom Cho; Jeong Wook Heo; Woo Yong Lee; Joon Oh Park; Ho Yeong Lim; Won Ki Kang; Young Suk Park; Woong-Yang Park; Jeeyun Lee; Hee Cheol Kim
Journal:  Oncotarget       Date:  2016-04-12

9.  The sirtuin 3 expression profile is associated with pathological and clinical outcomes in colon cancer patients.

Authors:  Chunyuan Liu; Zonghai Huang; Hong Jiang; Fujun Shi
Journal:  Biomed Res Int       Date:  2014-07-01       Impact factor: 3.411

10.  Spontaneous genomic alterations in a chimeric model of colorectal cancer enable metastasis and guide effective combinatorial therapy.

Authors:  Yinghui Zhou; William M Rideout; Angela Bressel; Sireesha Yalavarthi; Tong Zi; Darren Potz; Samuel Farlow; Joelle Brodeur; Anthony Monti; Shailaja Reddipalli; Qiurong Xiao; Steve Bottega; Bin Feng; M Isabel Chiu; Marcus Bosenberg; Joerg Heyer
Journal:  PLoS One       Date:  2014-08-27       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.